International Society for Cutaneous Lymphomas Pandemic Section (ICLYPS) Analysis of CTCL Outcomes During the COVID-19 Pandemic: A Retrospective Cohort Study - Supplementary Tables

We performed a retrospective analysis of data from the electronic medical records at nine international academic medical centers in seven countries from March-October 2020, including 149 patients, actively managed with an established diagnosis of cutaneous lymphoma. Patient demographics, date of diagnosis, staging details, treatment details, delays or changes to treatment regimens, disease outcomes and COVID-19 disease history including the source of transmission was recorded. Treatment was delayed for 53.0% of patients for a mean of 3.2 months (range: 10 days to 10 months). Adjusting for age, race, biological sex, COVID-19 status and disease stage, treatment delay was associated with a significant risk of disease relapse or progression across all stages (OR 5.00 (95% CI [2.38, 11.0], p-value <0.001) and, for each additional month that a patient experienced treatment delay, the odds of disease progression increased by 37.0% (OR 1.37 (95% CI [1.14, 1.70], p-value <0.001). A total of 28 (18.8%) patients with CTCL were diagnosed with COVID-19, none acquired from outpatient office visits. Patients who contracted COVID-19 did not have a statistically significant increase in odds of disease progression compared to COVID-negative patients (OR 0.41 (95% CI [0.15, 1.08], p-value = 0.07).本研究对2020年3月至10月期间，来自7个国家的9家国际学术医疗中心的电子病历数据开展回顾性分析，纳入149例经确诊并接受规范管理的皮肤淋巴瘤患者。研究记录了患者的人口学特征、确诊日期、疾病分期详情、治疗方案细节、治疗方案的延迟或调整情况、疾病转归，以及包括传播来源在内的新冠病毒感染病史。其中53.0%的患者出现治疗延迟，平均延迟时长为3.2个月（范围：10天至10个月）。在调整年龄、种族、生物学性别、新冠感染状态及疾病分期等混杂因素后，治疗延迟与所有分期患者的疾病复发或进展风险显著相关（比值比OR=5.00，95%置信区间CI=[2.38, 11.0]，p<0.001）；且患者每额外延迟治疗1个月，疾病进展的比值比升高37.0%（OR=1.37，95%CI=[1.14, 1.70]，p<0.001）。共计28例（18.8%）皮肤T细胞淋巴瘤（CTCL）患者确诊感染新冠病毒，无一例感染来源于门诊就诊。与新冠病毒阴性患者相比，感染新冠病毒的患者疾病进展的比值比未出现统计学意义的升高（OR=0.41，95%CI=[0.15, 1.08]，p=0.07）。